Physician profile
Mohammad Baig
NPI 1982640249
$2,359.19
in general payments reported to CMS, 2019-2025
24 companies · $918 in 2025
The $918 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $17.61 · 2021: $53.13 · 2022: $238 · 2023: $306 · 2024: $640 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,865.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,864.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $778.36 | 2022-2025 | Ozempic, Rybelsus, Tresiba |
| Bayer Healthcare Pharmaceuticals INC. | $299.99 | 2024-2025 | |
| Abbott Laboratories | $207.60 | 2019-2024 | Freestyle Libre 3 |
| Corcept Therapeutics | $181.30 | 2024-2025 | Korlym |
| Insulet Corporation | $126.57 | 2019-2024 | Omnipod |
| Amgen INC. | $97.67 | 2021-2025 | Tepezza |
| Medtronic, INC. | $84.26 | 2024-2025 | Abre, Minimed 780g |
| Xeris Pharmaceuticals, INC. | $74.84 | 2024-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $73.69 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Abbvie INC. | $60.47 | 2021-2023 | Synthroid |
| Dexcom, INC. | $48.02 | 2022-2023 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $45.77 | 2025 | Twiist |
| Lifescan, INC. | $41.51 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.18 | 2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $34.83 | 2019-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $27.60 | 2025 | Isturisa |
| Amneal Pharmaceuticals LLC | $22.16 | 2024 | Unithroid |
| Cequr Corporation | $20.84 | 2023 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $19.69 | 2019 | |
| Madrigal Pharmaceuticals | $18.55 | 2025 | Rezdiffra |
| Renalytix Ai, INC. | $17.58 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Averitas Pharma INC. | $16.91 | 2025 | Qutenza |
| Glaxosmithkline, LLC. | $14.16 | 2025 | Arexvy, Shingrix |
| Cumberland Pharmaceuticals, INC. | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Baig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.